IBIO iBio Inc
- 2.7200
- +0.0100+0.37%
iBio Inc News
Express News | Ibio Discovers Novel Antibody Targeting Activin E in Collaboration With Astralbio
IBio Discovers Novel Antibody Targeting Activin E in Collaboration With AstralBio
iBio (IBIO.US) has obtained the license for the iBio-600 antibody, which will expand the cardiac metabolism and obesity treatment program.
iBio (IBIO.US) announced on Thursday that it has obtained the license for long-acting myostatin-inhibitory antibodies from AstralBio, thereby expanding its cardiovascular metabolism and obesity treatment development projects.
Express News | Ibio Inc: Astralbio Eligible for Development & Commercialization Milestone Payments Totaling up to $28 Mln
Express News | Ibio Inc: Plans to Enter Into Clinical Investigation in Obesity and Cardiometabolic Disorders in 2026
IBio Expands Obesity Program With $750K Upfront Payment and $28M AstralBio Partnership
IBio Expands Cardiometabolic and Obesity Program With Anti-Myostatin Antibody Discovered Using Its Proprietary Platform, In-Licensed From AstralBio
IBio Inc. Stock Rises Tuesday, Outperforms Market
IBio Analyst Ratings
Lucid Capital Initiates IBio Inc(IBIO.US) With Buy Rating, Announces Target Price $6
The small Kennedy effect: Major exodus of pharmaceutical stocks in the USA
Several weeks have passed since Trump nominated Alex Azar as Secretary of Health and Human Services, yet the trend of investors withdrawing from the medical care sector has not diminished. So far this year, the performance of the Health Care Select Sector SPDR Fund (XLV) in comparison to the S&P 500 index is approaching the lowest level in the past thirty years. Goldman Sachs believes that significant economic events may need to occur + related policies become clearer + corporate profit expectations are raised in order to attract investors back.
IBio Names David Arkowitz and António Parada to Its Board >IBIO
Express News | Ibio Strengthens Board With Appointment of Two New Independent Directors
Press Release: IBio Strengthens Board With Appointment of Two New Independent Directors
Trump Nominates Marty Makary For FDA Commissioner
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Sell-off of US vaccine stocks intensifies! Analyst: Little Kennedy brings uncertainty to the entire industry.
1. On Friday Eastern Time, vaccine manufacturers' stocks plummeted as Donald Trump selected vaccine skeptic Kennedy as Health Secretary, causing industry uncertainty. Moderna, Novavax, Pfizer, and other stock prices were all affected. 2. Analysts pointed out that Kennedy's anti-vaccine stance may weaken public trust in vaccines, leading to a decrease in the vaccination rate in the USA, increasing the risk of outbreaks of diseases such as measles and whooping cough.
Vaccines stocks in the usa collectively plummet! Trump surprisingly appoints an anti-vaccine advocate as the Secretary of Health in the usa.
① Trump nominated Robert F. Kennedy Jr. as the new Secretary of Health and Human Services, which triggered a sell-off in vaccine companies; ② Kennedy advocates very radical views, opposing vaccines since 2005, and questioning the transparency of the usa government in public health information.
IBio GAAP EPS of -$0.46 In-line
iBio Inc | 8-K: iBio Reports Fiscal First Quarter 202 5 Financial Results
No Data